306 A recent randomised clinical trial of prazosin failed to reach statistical significance, but may have been underpowered. 307 The mechanism by which reducing noradrenaline in advanced disease may reduce symptoms of agitation remains unclear.
← all excerpts
Noradrenergic therapies in neurodegenerative disease: from symptomatic to disease modifying therapy?
1
—
—